Nissim Darvish, M.D., Ph.D., is a Senior Managing Director. Nissim is a veteran of the lifescience industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. Nissim spent eight years with Pitango, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents, authored over 20 publications and received eight prizes and awards. Nissim has served on boards of multiple companies, including Inotek Pharmaceuticals Inc., SuperDimension, Vascular Biogenics and Inca Medical.

Back to Top

Anat Naschitz, LLB, MBA, is a Managing Director. Anat has over 15 years of international healthcare operational and investment experience. Anat spent seven years with McKinsey & Company in London, where she was an Associate Partner, managing strategy and M&A projects for senior leadership of the world's preeminent pharmaceutical and biotechnology companies. Among other accomplishments, Anat led pharmaceutical spinout work resulting in the creation of two European biotech companies, which subsequently had IPOs for over $1 billion. Anat then joined Apax Partners, where she focused on life sciences investments. More recently, Anat worked with investors and companies on transactions and corporate strategy and served as a director/advisor to the boards of multiple medical device and biopharmaceutical companies. She earned her MBA at INSEAD and her LLB at Tel Aviv University.

Back to Top

Erez Chimovits, M.Sc, MBA, is a Managing Director. Erez has 14 years of operational experience, including 10 years of senior managerial experience in publicly traded biotech companies. Prior to joining OrbiMed Erez was the CEO of NasVax (TASE:NSVX), a company developing improved vaccine and immunotherapeutic products. Under Erez' leadership NasVax acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Erez spent more than seven years with Compugen (Nasdaq:CGEN), most recently as President, Compugen USA Inc. and Executive VP, Commercial Operations, Compugen Ltd. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions with blue chip pharmaceutical companies including Johnson & Johnson, Novartis, Teva, Abbott, Medarex and others. Erez earned his MBA, M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.

Back to Top

Aya Jakobovits, Ph.D., is a Venture Partner on the Israel team. She was most recently the Executive Vice President, Head, Research and Development at Agensys, Inc. Agensys, a subsidiary of Astellas Pharma, was acquired for up to $537 million in 2007. Previously Aya was Director, Discovery Research and Principal Scientist at Abgenix Inc., which she founded. Abgenix was acquired by Amgen for $2.2 billion. OrbiMed had been an early investor in both Abgenix and Agensys. Aya obtained a B.Sc. in Chemistry from the Hebrew University in Jerusalem, and an M.Sc. in Chemistry and Ph.D. in Life Sciences from the Weizmann Institute of Science in Rehovot, Israel. She conducted her postdoctoral research at the University of California, San Francisco, and at Genentech Inc.

Back to Top